Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




Events

10 Feb 2026 - 13 Feb 2026
17 Apr 2026 - 21 Apr 2026

Molecular Biomarker Test Detects Sepsis

By LabMedica International staff writers
Posted on 22 Dec 2011
Gene expression biomarkers have been utilized to distinguish patients with sepsis and those with Systemic Inflammatory Response Syndrome (SIRS).

Patients with sepsis need to be differentiated from those who had undergone major open surgery and had clinical outcomes consistent with systemic inflammation due to physical trauma and wound healing.

Scientists working for Athlomics Pty Ltd., (Toowong, QLD, Australia) in collaboration with various local hospitals conducted a multicenter, prospective clinical trial across four tertiary critical care settings in Australia. More...
Twenty-seven sepsis patients were recruited provided they had clinical evidence of systemic infection based on microbiology diagnoses. A participant group of 38 was postsurgical (PS), was recruited preoperatively, and their blood samples collected within 24 hours following surgery. There was also a healthy control (HC) group of 20 participants.

Each participant had minimally 5 mL of PAXgene (PreAnalytix; Hombrechtikon, Switzerland) blood collected for leucocyte ribonucleic acid (RNA) isolation and gene expression analyses. Studies were conducted to evaluate transcriptional profiles in circulating white blood cells applying a set of 42 molecular markers that had been identified a priori using the Affymetrix array (Santa Clara, CA, USA) and multiplex tandem-polymerase chain reaction (MT-PCR) assays. An algorithm was used to create a machine learning diagnostic rule to predict sepsis outcomes.

Based on preliminary microarray analyses comparing sepsis groups and HC, a panel of 42-gene expression markers were identified that represented key innate and adaptive immune function, cell cycling, leucocyte differentiation, extracellular remodeling, and immune modulation pathways. Comparisons against Gene Expression Omnibus (GEO) data confirmed the definitive separation of the sepsis cohort. Quantitative PCR results suggest the capacity for this test to differentiate severe systemic inflammation from HC is 92%. The area under the curve (AUC) receiver operator characteristics (ROC) curve findings demonstrated sepsis prediction within a mixed inflammatory population, was between 86% and 92%.

The authors concluded that this novel molecular biomarker test has a clinically relevant sensitivity and specificity profile, and has the capacity for early detection of sepsis via the monitoring of critical care patients. These findings suggest that this sepsis gene-expression test is robust and ongoing studies will determine whether it performs equally well when applied to different patient populations and ethnic groups. The study was first published online on June 20, 2011, in the journal Critical Care.

Related Links:

PreAnalytix
Affymetrix




Gold Member
Immunochromatographic Assay
CRYPTO Cassette
POC Helicobacter Pylori Test Kit
Hepy Urease Test
Gel Cards
DG Gel Cards
Hemodynamic System Monitor
OptoMonitor
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Immunology

view channel
Image: Circulating tumor cells isolated from blood samples could help guide immunotherapy decisions (Photo courtesy of Shutterstock)

Blood Test Identifies Lung Cancer Patients Who Can Benefit from Immunotherapy Drug

Small cell lung cancer (SCLC) is an aggressive disease with limited treatment options, and even newly approved immunotherapies do not benefit all patients. While immunotherapy can extend survival for some,... Read more

Microbiology

view channel
Image: New evidence suggests that imbalances in the gut microbiome may contribute to the onset and progression of MCI and Alzheimer’s disease (Photo courtesy of Adobe Stock)

Comprehensive Review Identifies Gut Microbiome Signatures Associated With Alzheimer’s Disease

Alzheimer’s disease affects approximately 6.7 million people in the United States and nearly 50 million worldwide, yet early cognitive decline remains difficult to characterize. Increasing evidence suggests... Read more

Technology

view channel
Image: Vitestro has shared a detailed visual explanation of its Autonomous Robotic Phlebotomy Device (photo courtesy of Vitestro)

Robotic Technology Unveiled for Automated Diagnostic Blood Draws

Routine diagnostic blood collection is a high‑volume task that can strain staffing and introduce human‑dependent variability, with downstream implications for sample quality and patient experience.... Read more

Industry

view channel
Image: Roche’s cobas® Mass Spec solution enables fully automated mass spectrometry in routine clinical laboratories (Photo courtesy of Roche)

New Collaboration Brings Automated Mass Spectrometry to Routine Laboratory Testing

Mass spectrometry is a powerful analytical technique that identifies and quantifies molecules based on their mass and electrical charge. Its high selectivity, sensitivity, and accuracy make it indispensable... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.